

## Appendix: Tables

1.	Sales January to September 2020 and 2019 .....	2
2.	Quarterly sales and constant exchange rate sales growth by Division in 2020 and 2019 .....	3
3.	Pharmaceuticals Division – Top-selling pharmaceuticals sales and constant exchange rate growth YTD September 2020 vs. YTD September 2019 .....	4
4.	Pharmaceuticals Division – New products sales and constant exchange rate growth YTD September 2020 vs. YTD September 2019 .....	5
5.	Top 20 Pharmaceuticals Division product sales and constant exchange rate growth YTD September 2020 vs. YTD September 2019 .....	6
6.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth .....	7
7.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth United States .....	8
8.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Europe .....	9
9.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Japan .....	10
10.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth International* .....	11

**1. Sales January to September 2020 and 2019**

CHF millions	Nine months ended 30 September		% change	
	2020	2019	At CER	In CHF
Pharmaceuticals Division	34,317	36,559	-1	-6
United States	18,389	20,036	-4	-8
Europe	6,268	6,310	4	-1
Japan	2,802	3,076	-6	-9
International*	6,858	7,137	6	-4
Diagnostics Division	9,662	9,507	9	2
Roche Group	43,979	46,066	1	-5

\* Asia-Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, Others

## 2. Quarterly sales and constant exchange rate sales growth by Division in 2020 and 2019

CHF millions	Q3 2019	% change vs. Q3 2018	Q4 2019	% change vs. Q4 2018	Q1 2020	% change vs. Q1 2019	Q2 2020	% change vs. Q2 2019	Q3 2020	% change vs. Q3 2019
Pharmaceuticals Division	12,365	15	11,957	8	12,262	7	10,940	-6	11,115	-4
United States	6,666	14	6,675	11	6,616	3	5,848	-10	5,925	-5
Europe	2,089	5	2,143	6	2,264	14	1,926	-3	2,078	2
Japan	1,088	14	1,067	3	948	3	960	-7	894	-13
International*	2,522	27	2,072	2	2,434	16	2,206	5	2,218	-2
Diagnostics Division	3,232	6	3,443	1	2,881	5	3,198	2	3,583	18
Roche Group	15,597	13	15,400	6	15,143	7	14,138	-4	14,698	1

\*Asia-Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, Others

3. Pharmaceuticals Division – Top-selling pharmaceuticals sales and constant exchange rate growth YTD September 2020 vs. YTD September 2019

Top-selling pharmaceuticals January - September 2020	Total		United States		Europe		Japan		International*	
	CHF m	%	CHF m	%	CHF m	%	CHF m	%	CHF m	%
Avastin	4,023	-22	1,489	-34	1,082	-16	534	-17	918	-6
MabThera/Rituxan	3,443	-27	2,365	-27	304	-32	48	-41	726	-21
Ocrevus	3,274	29	2,610	23	490	51	-	-	174	75
Herceptin	3,079	-31	1,161	-44	522	-32	109	-40	1,287	-13
Perjeta	2,929	17	1,138	3	858	12	219	12	714	60
Actemra/RoActemra	2,134	33	942	42	568	13	267	-7	357	117
Tecentriq	2,015	64	1,166	46	437	102	225	86	187	96
Hemlibra	1,575	79	1,020	68	261	155	227	53	67	183
Xolair	1,451	2	1,451	2	-	-	-	-	-	-
Kadcyla	1,295	37	617	44	404	36	63	5	211	33

\* Asia-Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, Others

4. Pharmaceuticals Division – New products sales and constant exchange rate growth YTD September 2020 vs. YTD September 2019

New products January - September 2020	Total		United States		Europe		Japan		International*	
	CHF m	%	CHF m	%	CHF m	%	CHF m	%	CHF m	%
Erivedge	210	12	141	12	46	6	-	-	23	27
Perjeta	2,929	17	1,138	3	858	12	219	12	714	60
Kadcyla	1,295	37	617	44	404	36	63	5	211	33
Gazyva/Gazyvaro	472	27	222	33	155	31	51	15	44	9
Esbriet	844	9	602	10	198	7	-	-	44	9
Cotellic	39	-3	8	5	16	-31	-	-	15	57
Alecensa	841	35	257	17	193	32	173	10	218	116
Tecentriq	2,015	64	1,166	46	437	102	225	86	187	96
Ocrevus	3,274	29	2,610	23	490	51	-	-	174	75
Hemlibra	1,575	79	1,020	68	261	155	227	53	67	183
Xofluza	28	286	26	297	-	-	-	-	2	144
Polivy	126	**	84	312	41	**	-	-	1	-
Rozlytrek	15	319	13	258	-	-	2	**	-	-
Phesgo	7	-	7	-	-	-	-	-	-	-
Enspryng	7	-	5	-	-	-	2	-	-	-
Evrysdi	8	-	8	-	-	-	-	-	-	-

\* Asia-Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, Others

\*\* Over 500%

5. Top 20 Pharmaceuticals Division product sales and constant exchange rate growth YTD September 2020 vs. YTD September 2019

CHF millions January - September 2020	Total		United States		Europe		Japan		International*	
	CHF m	%	CHF m	%	CHF m	%	CHF m	%	CHF m	%
Avastin	4,023	-22	1,489	-34	1,082	-16	534	-17	918	-6
MabThera/Rituxan	3,443	-27	2,365	-27	304	-32	48	-41	726	-21
Ocrevus	3,274	29	2,610	23	490	51	-	-	174	75
Herceptin	3,079	-31	1,161	-44	522	-32	109	-40	1,287	-13
Perjeta	2,929	17	1,138	3	858	12	219	12	714	60
Actemra/RoActemra	2,134	33	942	42	568	13	267	-7	357	117
Tecentriq	2,015	64	1,166	46	437	102	225	86	187	96
Hemlibra	1,575	79	1,020	68	261	155	227	53	67	183
Xolair	1,451	2	1,451	2	-	-	-	-	-	-
Kadcyla	1,295	37	617	44	404	36	63	5	211	33
Lucentis	1,120	-14	1,120	-14	-	-	-	-	-	-
Activase/TNKase	1,005	3	966	3	-	-	-	-	39	7
Esbriet	844	9	602	10	198	7	-	-	44	9
Alecensa	841	35	257	17	193	32	173	10	218	116
Pulmozyme	500	-5	343	-8	99	5	1	32	57	-6
Gazyva	472	27	222	33	155	31	51	15	44	9
CellCept	462	-2	47	-25	119	-4	59	-3	237	5
Mircera	369	-14	-	-	45	-7	114	-22	210	-11
Madopar	280	9	-	-	81	1	-	-	199	13
Xeloda	253	-16	5	-72	12	2	25	-57	211	-2

\* Asia-Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, Others

6. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth

CHF millions	Q3 2019	% change vs. Q3 2018	Q4 2019	% change vs. Q4 2018	Q1 2020	% change vs. Q1 2019	Q2 2020	% change vs. Q2 2019	Q3 2020	% change vs. Q3 2019
Avastin	1,806	8	1,608	-6	1,497	-13	1,338	-24	1,188	-30
MabThera/Rituxan	1,620	-1	1,518	-6	1,389	-15	1,051	-32	1,003	-33
Ocrevus	929	48	1,044	55	1,112	38	964	12	1,198	37
Herceptin	1,535	-7	1,240	-24	1,207	-24	993	-33	879	-38
Perjeta	910	33	857	16	1,011	22	930	12	988	17
Actemra/RoActemra	571	9	605	5	666	30	795	40	673	27
Tecentriq	515	154	578	136	644	99	653	54	718	49
Hemlibra	386	*	459	313	521	146	482	59	572	57
Xolair	513	3	484	0	468	3	490	1	493	3
Kadcyla	369	54	388	57	428	55	409	26	458	33
Lucentis	442	7	456	7	387	-13	341	-25	392	-5
Activase/TNKase	334	5	312	0	390	11	301	-3	314	1
Esbriet	281	6	316	9	292	22	274	2	278	5
Alecensa	235	50	220	11	268	43	272	27	301	37
Pulmozyme	191	7	189	-5	191	10	161	-10	148	-16
Gazyva	149	45	162	51	165	49	145	23	162	15
CellCept	177	3	154	-3	166	7	148	-2	148	-11
Mircera	167	11	142	5	126	-8	125	-7	118	-26
Madopar	94	22	84	9	98	5	96	23	86	2
Xeloda	103	-4	87	-13	86	-16	90	-12	77	-20

\* Over 500%

7. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth United States

CHF millions	Q3 2019	% change vs. Q3 2018	Q4 2019	% change vs. Q4 2018	Q1 2020	% change vs. Q1 2019	Q2 2020	% change vs. Q2 2019	Q3 2020	% change vs. Q3 2019
Avastin	742	1	647	-11	586	-27	471	-39	432	-37
MabThera/Rituxan	1,108	4	1,099	1	973	-14	720	-33	672	-35
Ocrevus	760	35	833	44	898	29	773	9	939	32
Herceptin	665	-6	533	-24	475	-38	373	-46	313	-49
Perjeta	370	8	370	4	395	-1	375	4	368	7
Actemra/RoActemra	236	11	248	6	296	44	396	65	250	15
Tecentriq	329	198	343	146	376	79	368	31	422	37
Hemlibra	254	*	308	302	353	119	311	51	356	50
Xolair	513	3	484	0	468	3	490	1	493	3
Kadcyla	170	87	187	108	204	68	200	36	213	34
Lucentis	442	7	456	7	387	-13	341	-25	392	-5
Activase/TNKase	320	5	297	-1	376	10	288	-3	302	1
Esbriet	199	0	233	6	202	20	200	4	200	8
Alecensa	82	15	98	23	84	29	84	7	89	17
Pulmozyme	138	9	136	-4	128	10	116	-10	99	-22
Gazyva	65	24	74	48	79	48	65	23	78	29
CellCept	23	-30	17	-15	18	-15	14	-31	15	-29
Mircera	-	-	-	-	-	-	-	-	-	-
Madopar	-	-	-	-	-	-	-	-	-	-
Xeloda	3	-63	4	-53	3	-71	-1	-	3	-15

\* Over 500%

8. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Europe

CHF millions	Q3 2019	% change vs. Q3 2018	Q4 2019	% change vs. Q4 2018	Q1 2020	% change vs. Q1 2019	Q2 2020	% change vs. Q2 2019	Q3 2020	% change vs. Q3 2019
Avastin	435	4	439	1	423	-3	373	-13	286	-33
MabThera/Rituxan	147	-26	120	-33	123	-24	79	-44	102	-29
Ocrevus	127	154	157	112	156	79	141	26	193	56
Herceptin	233	-42	212	-39	193	-32	168	-33	161	-30
Perjeta	264	18	287	21	307	21	260	1	291	13
Actemra/RoActemra	172	3	178	3	209	27	173	2	186	10
Tecentriq	93	113	122	172	145	169	137	90	155	72
Hemlibra	45	211	57	202	78	216	68	92	115	171
Xolair	-	-	-	-	-	-	-	-	-	-
Kadcyla	108	20	120	28	132	43	125	26	147	39
Lucentis	-	-	-	-	-	-	-	-	-	-
Activase/TNKase	-	-	-	-	-	-	-	-	-	-
Esbriet	66	26	69	16	74	28	60	-3	64	-2
Alecensa	57	164	59	58	66	51	59	27	68	22
Pulmozyme	31	2	33	-2	37	12	31	0	31	3
Gazyva	44	30	50	38	56	57	45	13	54	26
CellCept	43	3	43	-1	48	15	32	-20	39	-8
Mircera	17	-8	16	-8	17	6	14	-13	14	-14
Madopar	28	6	29	7	29	13	24	-11	28	2
Xeloda	5	16	4	7	5	25	4	4	3	-18

9. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Japan

CHF millions	Q3 2019	% change vs. Q3 2018	Q4 2019	% change vs. Q4 2018	Q1 2020	% change vs. Q1 2019	Q2 2020	% change vs. Q2 2019	Q3 2020	% change vs. Q3 2019
Avastin	241	9	206	-13	181	-5	182	-19	171	-25
MabThera/Rituxan	26	-45	25	-37	17	-39	16	-45	15	-38
Ocrevus	-	-	-	-	-	-	-	-	-	-
Herceptin	62	-1	58	-15	40	-26	37	-45	32	-46
Perjeta	81	125	79	67	74	49	75	11	70	-9
Actemra/RoActemra	107	13	103	1	89	6	92	-8	86	-15
Tecentriq	50	66	63	68	69	111	79	94	77	62
Hemlibra	71	*	79	472	74	207	77	36	76	13
Xolair	-	-	-	-	-	-	-	-	-	-
Kadcyla	22	10	20	-5	18	3	23	3	22	7
Lucentis	-	-	-	-	-	-	-	-	-	-
Activase/TNKase	-	-	-	-	-	-	-	-	-	-
Esbriet	-	-	-	-	-	-	-	-	-	-
Alecensa	57	14	55	-1	53	15	62	8	58	8
Pulmozyme	-	-	1	14	-	-	-	-	1	40
Gazyva	25	390	20	145	15	95	21	65	15	-36
CellCept	21	1	22	-1	19	0	21	-6	19	-3
Mircera	51	-6	51	-14	37	-17	38	-29	39	-20
Madopar	-	-	-	-	-	-	-	-	-	-
Xeloda	16	-44	14	-53	10	-54	8	-60	7	-56

\* Over 500%

10. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth International\*

CHF millions	Q3 2019	% change vs. Q3 2018	Q4 2019	% change vs. Q4 2018	Q1 2020	% change vs. Q1 2019	Q2 2020	% change vs. Q2 2019	Q3 2020	% change vs. Q3 2019
Avastin	388	29	316	0	307	5	312	-6	299	-14
MabThera/Rituxan	339	3	274	-11	276	-9	236	-25	214	-30
Ocrevus	42	118	54	155	58	119	50	43	66	74
Herceptin	575	20	437	-16	499	4	415	-14	373	-28
Perjeta	195	122	121	19	235	83	220	50	259	52
Actemra/RoActemra	56	16	76	15	72	27	134	123	151	209
Tecentriq	43	132	50	109	54	101	69	120	64	74
Hemlibra	16	**	15	**	16	**	26	319	25	58
Xolair	-	-	-	-	-	-	-	-	-	-
Kadcyla	69	78	61	50	74	63	61	12	76	30
Lucentis	-	-	-	-	-	-	-	-	-	-
Activase/TNKase	14	2	15	8	14	27	13	4	12	-5
Esbriet	16	20	14	31	16	23	14	3	14	5
Alecensa	39	154	8	-64	65	97	67	107	86	141
Pulmozyme	22	5	19	-15	26	8	14	-25	17	-6
Gazyva	15	31	18	43	15	7	14	16	15	5
CellCept	90	17	72	-1	81	11	81	18	75	-10
Mircera	99	27	75	28	72	-6	73	13	65	-31
Madopar	66	40	55	11	69	2	72	40	58	2
Xeloda	79	17	65	10	68	1	79	8	64	-13

\* Asia-Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, Others

\*\* Over 500%